In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including ...

Recursion Pharmaceuticals has been trying to rebuild momentum after a steep five year decline in shareholder returns, yet its ...

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

These aren't for the faint of heart.

Recursion Pharmaceuticals combines artificial intelligence, automation, and biotechnology research across multiple ...

Vitalik Buterin outlined the updated Lean Ethereum roadmap, a 3-to-4-year plan covering quantum resistance, 10,000 TPS ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

Autonomous AI post-training reached frontier scale for the first time: NVIDIA researchers published a paper showing an AI ...

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from ...

The frontier model is a commodity. The companies winning are the ones that own distribution, and venture capital is paying up ...

Anthropic’s latest bombshell about AI designing itself and the dangers of the same, must be taken with a pinch of salt, ...